BioSpace News Archive

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced positive topline data from an interim analysis of its Phase 2 clinical trial of imsidolimab

In conjunction with OCD Awareness Week, BrainsWay partners with mental health influencers and patients to increase education around misrepresentation of the disorder

Aesthetic Medical International Holdings Group Limited (the “Company”) (NASDAQ: AIH), a leading provider of aesthetic medical services in China, today announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to US$6.0 million worth of its American depositary shares over the next 12-month period, effective until October 12, 2021,

A health care option for every health need and budget, including individual and family plans on the individual exchanges, Prescription Drug Plans and Medicare Supplement plans

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced that Robert R. Ford, MD, will join the staff as Senior Advisor, Chief Medical Officer Emeritus.

The Pancreatic Cancer Action Network (PanCAN) announced today the launch of Precision PromiseSM, the first of its kind adaptive clinical trial platform for pancreatic cancer patients.

Nasus Pharma a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) product portfolio to address acute medical conditions and public health threats, today announced data from a prospective clinical post marketing users survey demonstrating that Taffix™

Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that it has dosed the first patient in its phase 1/2 adaptive-design clinical trial of its lead-product-candidate, LNS8801, in combination with KEYTRUDA®

SK Biopharmaceuticals and Ono Pharmaceutical announced that they have entered into an exclusive licensing agreement for Ono to develop and commercialize cenobamate in Japan. Cenobamate is a treatment for partial-onset seizures (POS) that received FDA approval in 2019.

CEFALY Technology today announced that the U.S. Food and Drug Administration (FDA) has cleared the CEFALY DUAL medical device as an over-the-counter (OTC) product